American Society of Hematology

SHERPA: Blue

People

  1. Yahalom
    Yahalom
  2. Zelenetz
    Zelenetz
  3. Noy
    Noy
  4. Imber
    Imber
  5. Palomba
    Palomba
  6. Hamlin
    Hamlin
  7. Horwitz
    Horwitz
  8. Moskowitz
    Moskowitz
  9. Schoder
    Schoder
  10. Kumar
    Kumar

Groups

  1. Radiation Oncology, Department of (113)
  2. Survivorship Research (113)
  3. Department of Medicine (96)
  4. Hematologic Malignancies, Division of (95)
  5. Center for Hematologic Malignancies (91)
  6. Lymphoma (78)
  7. Graduate Medical Education (38)
  8. Hematology-Oncology Fellows (36)
  9. Population Sciences Research Program (31)
  10. Bone Marrow Transplant (30)
Search Within
  1. "Joachim Yahalom"
Formats
  1. Meeting Abstract (87)
  2. Journal Article (24)
  3. Guidelines (1)
  4. Review (1)
Groups
  1. Radiation Oncology, Department of (113)
  2. Survivorship Research (113)
  3. Department of Medicine (96)
  4. Hematologic Malignancies, Division of (95)
  5. Center for Hematologic Malignancies (91)
  6. Lymphoma (78)

More Groups

People
  1. Joachim Yahalom (113)
  2. Andrew Zelenetz (57)
  3. Ariela Noy (40)
  4. Brandon Imber (38)
  5. Craig Moskowitz (38)
  6. David Straus (35)

More People

Years
  1. 2025 (1)
  2. 2024 (12)
  3. 2023 (14)
  4. 2022 (9)
  5. 2021 (10)
  6. 2020 (7)

More Years

Publications
  1. Blood (103)
  2. Blood Advances (10)

Results (113)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: An ILROG multicenter study
    Journal Article

    Yegya-Raman, N.; Plastaras, J. P.; Wright, C. M.; Chelius, M.; Zhang, S.; Baron, J. A.; Hubbeling, H.; Sim, A. J.; Robinson, T. J.; Jain, M. D.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • CTEP 10590, NORM: Nodular lymphocyte predominant Hodgkin lymphoma patients treated in a randomized phase II trial with either rituximab or mosunetuzumab
    Meeting Abstract

    Steiner, R.; Bock, A. M.; Herrera, A. F.; Zulfa, O.; Hoffmann, M.; Ibrahimi, S.; Galanina, N.; Lee, H. J.; Green, M.; Lin, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Bridging radiotherapy may decrease inflammation prior to CAR-T cell therapy
    Meeting Abstract

    Patel, R. R.; Tward, A.; Fregonese, B.; Hubbeling, H.; Lapen, K.; Mankuzhy, N. P.; Raj, S. S.; Perales, M. A.; Shouval, R.; Yahalom, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Very low dose radiotherapy (VLDRT) with 4 Gy for potentially-curable indolent non-Hodgkin lymphomas
    Meeting Abstract

    Mankuzhy, N. P.; Imber, B. S.; Pammer, P.; Fregonese, B.; Cajo, A.; Cederquist, G.; Dreyfuss, A.; Lapen, K.; Patel, R. R.; Moore, Z. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Radiation therapy in a new era of multiple myeloma management: Trends of engagement and radiologic, biochemical, and cytogenetic correlates of outcomes and response
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Usmani, S. Z.; Mailankody, S.; Imber, B. S.; Yahalom, J.
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save